BBV152 is a whole-virion inactivated vaccine based on the Asp614Gly variant. BBV152 is
the first alum-imidazoquinolin-adjuvanted vaccine authorized for use in large populations …

The rapid expansion of the COVID-19 pandemic has made the development of a SARS-CoV-
2 vaccine a global health and economic priority. Taking advantage of versatility and rapid …

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered the
global coronavirus disease 2019 (COVID-19) pandemic. Although most infections cause a …

Introduction COVID-19 vaccines have been highly effective in reducing morbidity and
mortality during the pandemic. While primary series vaccination rates are generally high in …

T cells in COVID-19 — united in diversity | Nature Immunology Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …

Abstract Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), the etiological
agent of Coronavirus Diseases 2019 (COVID-19), triggers an adaptive immunity in the …

Due to the enormous economic, health, and social costs of the COVID-19 pandemic, there
are high expected social returns to investing in parallel in multiple approaches to …

The capacity of antibodies to engage with immune cells via the Fc region is important in
preventing and controlling many infectious diseases. The evolution of such antibodies …

Understanding and eliciting protective immune responses to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is an urgent priority. To facilitate these objectives …

COVID-19 is being extensively studied, and much remains unknown regarding the long-term
consequences of the disease on immune cells. The different arms of the immune system are …